Core Viewpoint - Palvella Therapeutics, Inc. has successfully closed an upsized public offering, raising $230 million to support the development of its therapies for rare skin diseases and vascular malformations [1][3]. Group 1: Offering Details - The public offering consisted of 1,840,000 shares of common stock, priced at $125.00 per share, including the full exercise of the underwriters' option for an additional 240,000 shares [1]. - The offering was managed by several financial institutions, including TD Cowen, Cantor, and Stifel, among others [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to advance the development of Palvella's product candidates, specifically QTORIN rapamycin and QTORIN pitavastatin, as well as for general corporate purposes including research and development expenses [3]. Group 3: Company Overview - Palvella Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for serious, rare skin diseases and vascular malformations, with no FDA-approved treatments currently available [6]. - The company's lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel, targets microcystic lymphatic malformations and other skin conditions, while QTORIN™ pitavastatin is aimed at treating disseminated superficial actinic porokeratosis [6].

Core Insights - Palvella Therapeutics announced positive topline results from the Phase 3 SELVA study of QTORIN™ rapamycin for treating microcystic lymphatic malformations, meeting its primary endpoint with a statistically significant improvement [2][3] - The company plans to submit a New Drug Application (NDA) to the FDA in the second half of 2026, with potential approval in the first half of 2027 [3][10] Study Results - The primary endpoint, the Microcystic Lymphatic Malformation Investigator Global Assessment (mLM-IGA), showed a mean improvement of +2.13 points (p<0.001) [5][6] - 95% of participants aged ≥ 6 who completed the efficacy evaluation improved on the mLM-IGA at Week 24, with 86% rated as "Much Improved" or "Very Much Improved" [6][9] - All four secondary efficacy endpoints also achieved statistical significance (all p<0.001) [2][5] Safety and Tolerability - QTORIN™ rapamycin was well-tolerated, with no drug-related serious adverse events reported and systemic rapamycin levels below 2 ng/mL at all timepoints [6][8] - Among the 50 participants, 70% experienced treatment-emergent adverse events, but all were rated mild or moderate [8][9] Future Plans - Palvella aims to present detailed results from the SELVA study at upcoming medical meetings and is advancing QTORIN™ rapamycin for other rare skin diseases [11] - The company has received Breakthrough Therapy, Orphan Drug, and Fast Track designations from the FDA for QTORIN™ rapamycin [10]

Core Viewpoint - Palvella Therapeutics, Inc. is set to announce topline results from the Phase 3 SELVA clinical trial for QTORIN™ rapamycin, aimed at treating microcystic lymphatic malformations, highlighting the company's focus on rare skin diseases and vascular malformations with no FDA-approved therapies available [1]. Company Overview - Palvella Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for serious, rare skin diseases and vascular malformations [3]. - The company is led by veterans in rare disease drug development and is focused on a broad pipeline of product candidates based on its patented QTORIN™ platform [3]. - Palvella's lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel, is in development for microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas [3]. - The second product candidate, QTORIN™ pitavastatin, is being developed for the topical treatment of disseminated superficial actinic porokeratosis [3]. Upcoming Events - A conference call and webcast will be held on February 24, 2026, at 8:00 am ET to discuss the topline results from the SELVA clinical trial [1]. - A press release with the topline results will be issued at approximately 6:30 am ET on the same day [1]. - The live webcast can be accessed through the company's website, and a replay will be available for 90 days [2].

Core Insights - Palvella Therapeutics has appointed Ashley Kline as Chief Commercial Officer to lead the commercial buildout for the planned standalone U.S. launch of QTORIN™ rapamycin anhydrous gel, targeting microcystic lymphatic malformations, a rare genetic disease affecting over 30,000 patients in the U.S. if approved [1][5] - Kline has a successful track record in the commercialization of therapies for rare diseases, having previously led the launch of Oxervate® at Dompé Pharmaceuticals, which achieved over $500 million in annual U.S. sales by 2023 [2][3] Company Overview - Palvella Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare genetic skin diseases without FDA-approved treatments [5] - The company is developing a pipeline of product candidates based on its patented QTORIN™ platform, with QTORIN 3.9% rapamycin anhydrous gel as its lead candidate currently in Phase 3 and Phase 2 clinical trials [5][6] Leadership and Strategy - Ashley Kline's leadership is expected to enhance Palvella's commercial organization, leveraging her experience in launching FDA-approved therapies for rare diseases [3][4] - Kline's approach emphasizes high-impact physician outreach and education, which contributed to the success of Oxervate® and is anticipated to be applied to Palvella's strategies [2][3]